Subscribe
Home
Issues
Online First
2023
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
2021
December 2021 - Vol 14 No 6
October 2021 - Vol 14 No 5
August 2021 - Vol 14 No 4
June 2021 - Vol 14 No 3
April 2021 - Vol 14 No 2
February 2021 - Vol 14 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Ovarian Cancer
HER2-Negative Breast Cancer
Triple-Negative Breast Cancer
Renal-Cell Carcinoma
Biosimilars
Gastrointestinal Cancer
Non–Small-Cell Lung Cancer
Categories
Conference Correspondent
ASCO 2021 - Breast Cancer
ASCO 2020 - Lung Cancer
ASH 2019 Wrap-Up
ASH 2019 MM
Web Exclusives
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Podcasts
Quick Quiz
CE
Authors
Patricia Stewart
Authored Items
Investigational mRNA-Based Vaccine May Offer New Hope for Patients With High-Risk Melanoma
By
Patricia Stewart
Online First
Emerging Therapies
During the 2023 American Association for Cancer Research Annual Meeting, researchers presented results from a phase 2b clinical trial demonstrating significant improvement in recurrence-free survival in patients with high-risk melanoma who were treated with a combination of an investigational personalized mRNA-based vaccine plus the immune checkpoint inhibitor pembrolizumab (Keytruda), compared with pembrolizumab alone.
Study Shows Need for Better Patient Education Regarding Link Between HPV and Cancer
By
Patricia Stewart
Online First
Cancer Prevention
Vaccination against human papillomavirus (HPV) can prevent several types of cancer, including cervical, oral/oropharyngeal, penile, and anal cancers. Unfortunately, vaccination rates, as well as public knowledge regarding the link between HPV and these cancers, are lagging, according to research presented during the 2023 American Association for Cancer Research Annual Meeting.
Pausing Endocrine Therapy to Become Pregnant Appears Safe for Women with Breast Cancer
By
Patricia Stewart
TON - April 2023 Vol 16, No 2
Breast Cancer
,
SABCS 2023
Young women with early-stage, hormone receptor–positive breast cancer attempting to become pregnant can safely pause endocrine therapy and resume it later, according to initial results from the international POSITIVE trial.
Older Patients of Color Less Likely to Receive Opioids for Cancer Pain at End of Life
By
Patricia Stewart
TON - April 2023 Vol 16, No 2
Healthcare Disparities
Older Black and Hispanic patients with advanced cancer are less likely than White patients to receive opioid medications for pain relief in the last weeks of life, according to the results of a recent study published in the
Journal of Clinical Oncology
.
Restrictive Diet May Not Be Necessary for Patients Undergoing HSCT
By
Patricia Stewart
TON - February 2023 Vol 16, No 1
ASH 2022
,
Supportive Care
Patients undergoing hematopoietic stem-cell transplantation (HSCT) do not derive any benefit from the restrictive diet frequently prescribed to prevent infections, according to the results of a clinical trial presented during the 64th American Society of Hematology Annual Meeting and Exposition.
Zanubrutinib Superior to Ibrutinib in Patients with Relapsed or Refractory CLL/SLL
By
Patricia Stewart
TON - February 2023 Vol 16, No 1
ASH 2022
,
Leukemia
,
Lymphoma
,
Hematologic Malignancies
A head-to-head phase 3 clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has found that zanubrutinib (Brukinsa), a next-generation Bruton tyrosine kinase (BTK) inhibitor, was more effective at preventing disease progression and is better tolerated than ibrutinib (Imbruvica), a first-generation BTK inhibitor that is the current standard of care for this population of patients.
Daily LMWH Not Beneficial in Pregnant Women with Inherited Thrombophilia and Recurrent Miscarriage
By
Patricia Stewart
TON - February 2023 Vol 16, No 1
ASH 2022
The use of low-molecular-weight heparin (LMWH) did not improve the rate of live births among pregnant women with inherited thrombophilia and recurrent miscarriage, according to results of a clinical trial presented during the 64th American Society of Hematology Annual Meeting and Exposition.
Addition of Radiation to Sorafenib Extends Survival in Advanced Hepatocellular Cancer
By
Patricia Stewart
TON - December 2022 Vol 15, No 6
ASTRO 2022 Highlights
,
Hepatocellular Carcinoma
According to findings from a phase 3 trial presented at the American Society for Radiation Oncology Annual Meeting 2022, the addition of stereotactic body radiation therapy (SBRT) to sorafenib (Nexavar) can lengthen overall survival (OS) and delay tumor progression in patients with unresectable advanced hepatocellular cancer (HCC) without compromising quality of life.
Blood Test Shows Promise for Detecting Cancers Early
By
Patricia Stewart
TON - December 2022 Vol 15, No 6
ESMO 2022 Highlights
New results from the PATHFINDER clinical trial suggest that a multicancer early detection blood test can accurately identify the presence of cancer in apparently healthy people.
Researchers Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers
By
Patricia Stewart
TON - December 2022 Vol 15, No 6
ESMO 2022 Highlights
,
Lung Cancer
Although it is well established that air pollution is associated with lung cancer, how this occurs has not been well described.
Shortened Radiation Schedule Safe and Effective in Men with High-Risk Prostate Cancer
By
Patricia Stewart
TON - December 2022 Vol 15, No 6
ASTRO 2022 Highlights
,
Prostate Cancer
A shortened course of radiation therapy is safe and effective for men with high-risk prostate cancer, according to the results of the phase 3 Prostate Cancer Study 5 (PCS5) trial.
Sexual Side Effects of Radiation Therapy Frequently Not Addressed with Female Patients
By
Patricia Stewart
TON - December 2022 Vol 15, No 6
ASTRO 2022 Highlights
Results from a new study found that radiation oncologists tend to discuss sexual side effects in women undergoing treatment for cervical cancer far less frequently than they discuss sexual side effects in men undergoing treatment for prostate cancer.
Neoadjuvant Durvalumab plus Tremelimumab Regimen Elicits Response in Advanced Ovarian Cancer
By
Patricia Stewart
TON - December 2022 Vol 15, No 6
Emerging Therapies
,
AACR Highlights
,
Ovarian Cancer
Dual immune checkpoint inhibition with the anti–PD-L1 antibody durvalumab (Imfinzi) and the investigational anti–CTLA-4 antibody tremelimumab combined with platinum-based chemotherapy showed promising clinical activity and a favorable safety profile in the neoadjuvant setting for patients with advanced ovarian cancer, according to results of a single-arm phase 2 study presented during the 2022 American Association for Cancer Research Annual Meeting.
Radiation Therapy May Be Safely Omitted for Some Older Patients with Luminal A Breast Cancer
By
Patricia Stewart
TON - October 2022 Vol 15, No 5
Breast Cancer
Endocrine therapy after breast-conserving surgery may be the only treatment needed in patients aged ≥55 years with low-grade luminal type A breast cancer, sparing them radiation therapy, including its side effects, financial burden, and inconvenience, according to findings from the single-arm LUMINA clinical trial reported at the 2022 American Society of Clinical Oncology Annual Meeting.
DETERMINATION Trial Confirms Importance of Individualizing Therapy for Newly Diagnosed Multiple Myeloma
By
Patricia Stewart
TON - October 2022 Vol 15, No 5
Hematologic Malignancies
In the phase 3 DETERMINATION trial—in which patients with newly diagnosed multiple myeloma were randomly assigned to a standard triplet regimen with and without autologous stem-cell transplantation (ASCT), with all receiving lenalidomide (Revlimid) maintenance therapy until disease progression—patients with ASCT had significantly longer progression-free survival (PFS) versus those who did not, but no difference in overall survival (OS) was observed between the 2 treatment arms.
Acalabrutinib Shows Promise in Marginal Zone Lymphoma
By
Patricia Stewart
TON - October 2022 Vol 15, No 5
Hematologic Malignancies
Treatment with acalabrutinib (Calquence) elicited a complete or partial response in ≥50% of patients with relapsed or refractory marginal zone lymphoma (MZL), according to interim results of a study presented by L. Elizabeth Budde, MD, PhD, Associate Professor, Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, at the 2022 American Society of Clinical Oncology Annual Meeting.
Integrating Digital Health Technology into Cancer Care
By
Patricia Stewart
TON - October 2022 Vol 15, No 5
ESMO
Digital health technologies have the potential to help transform patient care, but there are barriers that need to be overcome, said Deb Schrag, MD, MPH, George J. Bosl Chair, Department of Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), and Professor, Medicine, Weill Cornell Medical College, New York City, during a keynote lecture at the European Society for Medical Oncology Congress 2022.
Better Communication Between Oncologists and PCPs Is Needed to Eliminate the “Black Hole” of Cancer Care
By
Patricia Stewart
TON - August 2022 Vol 15, No 4
Survivorship
The number of cancer survivors continues to increase in the United States, which can be attributed to a growing and aging population, as well as recent advances in diagnosis and treatment.
First-Line Treatment with Dostarlimab Led to Remission in All Patients with Mismatch Repair-Deficient Rectal Cancer
By
Patricia Stewart
TON - August 2022 Vol 15, No 4
Rectal Cancer
First-line treatment with dostarlimab-gxly (Jemperli), a PD-1 inhibitor, achieved complete responses (CRs) in 100% of a subset of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, sparing them surgery, chemotherapy, and radiation, as of the latest follow-up.
First-Line Treatment with Olaparib plus Abiraterone Improves Radiographic Progression-Free Survival in Men with mCRPC Regardless of HRR Mutational Status
By
Patricia Stewart
TON - August 2022 Vol 15, No 4
Prostate Cancer
Combining the PARP inhibitor olaparib (Lynparza) with abiraterone acetate (Zytiga) led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival (PFS) versus abiraterone alone in patients with metastatic castration-resistant prostate cancer (mCRPC), regardless of homologous recombination repair (HRR) status, according to results of the phase 3 PROpel trial, presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Updated Results from KEYNOTE-564 Trial Confirm Benefit of Adjuvant Pembrolizumab in Patients with Renal-Cell Carcinoma at High Risk for Recurrence
By
Patricia Stewart
TON - August 2022 Vol 15, No 4
Renal-Cell Carcinoma
Adjuvant pembrolizumab (Keytruda) continued to provide a disease-free survival (DFS) benefit in patients with renal-cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy, according to 30-month follow-up data from the KEYNOTE-564 trial presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.
Neoadjuvant Nivolumab plus Chemotherapy: A New Standard of Care for Patients with Resectable NSCLC
By
Patricia Stewart
TON - August 2022 Vol 15, No 4
Lung Cancer
The phase 3 CheckMate-816 trial establishes a new standard of care for resectable non–small-cell lung cancer (NSCLC): neoadjuvant nivolumab (Opdivo) plus chemotherapy.
Black Patients with Cancer and COVID-19 More Likely to Have Treatment Disruptions Than White Patients
By
Patricia Stewart
TON - August 2022 Vol 15, No 4
COVID-19 & Cancer
According to data from the American Society of Clinical Oncology (ASCO) Survey on COVID-19 in Oncology Registry, black or African-American patients with cancer and COVID-19 were more likely than non-Hispanic white patients to experience delays or disruptions in cancer treatment during the pandemic.
Peptide-Based CoVac-1 Vaccine Shows Promise Against COVID-19 in Patients with Cancer
By
Patricia Stewart
TON - June 2022 Vol 15, No 3
AACR Highlights
Patients with cancer and immunoglobulin deficiency have compromised immune systems–based response to COVID-19 vaccines. A team of researchers in Germany has developed a multipeptide COVID-19 vaccine that boosts immunity in immunocompromised patients, according to results of a phase 1/2 trial reported at the 2022 American Association for Cancer Research annual meeting.
Genetic Score Makes PSA Screening More Accurate
By
Patricia Stewart
TON - June 2022 Vol 15, No 3
AACR Highlights
The use of a polygenic score (PGS) based on noncancer genetic variations in prostate-specific antigen (PSA) values helped to refine PSA screening in a large group of men without prostate cancer at baseline.
Sacituzumab plus Pembrolizumab Shows Encouraging Antitumor Activity in Metastatic Urothelial Cancer
By
Patricia Stewart
TON - June 2022 Vol 15, No 3
Urothelial Cancer
The addition of sacituzumab govitecan (Trodelvy), an antibody–drug conjugate, to the PD-1 inhibitor pembrolizumab (Keytruda) showed encouraging antitumor activity in checkpoint inhibitor–naïve patients with metastatic urothelial cancer, according to an analysis of the results of cohort 3 from the phase 2 TROPHY-U-01 clinical trial, which were presented at the 2022 ASCO Genitourinary Cancers Symposium by Petros Grivas, MD, PhD, Clinical Director, Genitourinary Cancers Program, University of Washington School of Medicine, Seattle, and Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle.
First-Line Sotorasib Demonstrates Durable Efficacy in Metastatic NSCLC with KRAS Mutation
By
Patricia Stewart
TON - June 2022 Vol 15, No 3
AACR Highlights
Sotorasib (Lumakras) continues to demonstrate durable efficacy in non–small-cell lung cancer (NSCLC) with
KRAS
p.G12C mutation at 2-year follow-up of the phase 2 CodeBreaK 100 clinical trial.
Elacestrant Elicits Positive Outcomes in Patients with Metastatic Breast Cancer Who Have Progressed on Previous Endocrine Therapy
By
Patricia Stewart
TON - April 2022 Vol 15, No 2
Breast Cancer
The investigational oral selective estrogen receptor degrader (SERD) elacestrant (RAD1901) significantly reduced the risk for death or disease progression and improved progression-free survival (PFS) compared with standard-of-care (SOC) endocrine therapy in patients with estrogen receptor (ER)-positive,
HER2
-negative metastatic breast cancer who had progressed on prior endocrine and targeted therapies, according to results of the phase 3 EMERALD clinical trial.
Addition of Ivosidenib to Azacitidine Improves Outcomes for Patients with AML and IDH1 Mutation
By
Patricia Stewart
TON - April 2022 Vol 15, No 2
ASH
POLARIX Trial Results Support Use of Polatuzumab Vedotin plus R-CHP as Frontline Treatment for DLBCL
By
Patricia Stewart
TON - April 2022 Vol 15, No 2
ASH
The antibody–drug conjugate polatuzumab vedotin-piiq (Polivy) added to R-CHP (rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) achieved a 27% reduction in the risk for progression or death compared with the standard regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line therapy for patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL).
Circulating Tumor DNA Profiling May Allow for Better Detection and Treatment of CNS Lymphoma
By
Patricia Stewart
TON - April 2022 Vol 15, No 2
ASH
According to results presented at the 2021 ASH Annual Meeting and Exposition, new sequencing technologies may overcome previous limitations of circulating tumor DNA (ctDNA) profiling in patients with central nervous system (CNS) lymphoma.
Amivantamab plus Lazertinib Combination Boosts Responses in Patients with Osimertinib-Resistant EGFR-Positive NSCLC
By
Patricia Stewart
TON - December 2021 Vol 14, No 6
Lung Cancer
Dual
EGFR
targeting with amivantamab-vmjw (Rybrevant) plus lazertinib (Leclaza) led to durable responses in more than one-third of chemotherapy-naïve patients with
EGFR
-positive non–small-cell lung cancer (NSCLC) whose disease had progressed on osimertinib (Tagrisso) therapy, according to a cohort analysis of the CHRYSALIS trial, presented at the American Society of Clinical Oncology 2021 virtual annual meeting.
Practice-Changing Results Observed with Adjuvant Pembrolizumab Therapy for Renal-Cell Carcinoma
By
Patricia Stewart
TON - October 2021 Vol 14, No 5
Renal-Cell Carcinoma
Treatment with the checkpoint inhibitor pembrolizumab (Keytruda) following surgery significantly extended disease-free survival (DFS) in patients with high-risk, clear-cell renal-cell carcinoma (RCC) compared with placebo, according to the results of the KEYNOTE-564 clinical trial. These findings were reported during a plenary session of the American Society of Clinical Oncology (ASCO) 2021 virtual annual meeting.
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2-Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
By
Patricia Stewart
TON - October 2021 Vol 14, No 5
Breast Cancer
The addition of the tyrosine kinase inhibitor tucatinib (Tukysa) to trastuzumab (Herceptin) and capecitabine continued to improve overall survival (OS) and progression-free survival (PFS) in patients with
HER2
-positive metastatic breast cancer, according to updated results from the pivotal HER2CLIMB trial.
Targeted Radiotherapy Extends Survival for Patients with Advanced Prostate Cancer
By
Patricia Stewart
TON - October 2021 Vol 14, No 5
Prostate Cancer
The addition of
177
Lu-PSMA-617, a radionuclide therapy that targets prostate-specific membrane antigen (PSMA), to standard-of-care treatment resulted in a 38% reduction in the risk for death versus standard of care alone in men with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase 3 VISION clinical trial, which were presented during a plenary session at the American Society of Clinical Oncology (ASCO) 2021 virtual annual meeting.
Sotorasib Shows Promising Activity in Patients with NSCLC and KRAS Mutation
By
Patricia Stewart
TON - October 2021 Vol 14, No 5
Lung Cancer
Approximately 13% of patients with lung adenocarcinoma harbor the
KRAS
p.G12C mutation, which is associated with poor clinical outcomes.
Addition of Copanlisib to Rituximab Improves Outcomes in Indolent NHL
By
Patricia Stewart
TON - June 2021 Vol 14, No 3
AACR Highlights
The addition of the
PI3K
inhibitor copanlisib (Aliopa) to rituximab (Rituxan) reduced the risk for disease progression or death by 48% compared with rituximab alone in patients with relapsed indolent non-Hodgkin lymphoma (NHL) in the phase 3 CHRONOS-3 clinical trial.
Selpercatinib Demonstrates Encouraging Activity in a Range of RET Fusion–Positive Solid Tumors
By
Patricia Stewart
TON - June 2021 Vol 14, No 3
AACR Highlights
Selpercatinib (Retevmo) demonstrated antitumor activity in
RET
fusion–positive tumors other than lung cancer and thyroid cancer, according to interim results from the phase 1/2 LIBRETTO-001 clinical trial.
Study Identifies Inherited Pathogenic Germline Variants in Pediatric Neuroblastoma
By
Patricia Stewart
TON - June 2021 Vol 14, No 3
AACR Highlights
Researchers have identified 2 inherited pathogenic genetic variants in patients with pediatric neuroblastoma, according to results from a study presented at the 2021 virtual American Association for Cancer Research annual meeting.
Becoming Pregnant Is Feasible But Less Likely for Breast Cancer Survivors
By
Patricia Stewart
TON - June 2021 Vol 14, No 3
Survivorship
According to results from a large meta-analysis, breast cancer survivors of child-bearing age are less likely than the general population to get pregnant and face greater risk for certain complications, including preterm labor and cesarean section.
Current and Future Effects of the COVID-19 Pandemic on Cancer Care
By
Patricia Stewart
TON - June 2021 Vol 14, No 3
COVID-19
The COVID-19 pandemic caused significant disruptions to virtually all aspects of oncology care. There has been a steep drop in cancer diagnoses and screenings—a result of shelter-in-place policies instituted early on, as well as ongoing patient fears about returning to healthcare facilities for new appointments or follow-up care.
Enfortumab Vedotin Prolongs Survival in Patients with Metastatic Urothelial Cancer
By
Patricia Stewart
TON - June 2021 Vol 14, No 3
Urothelial Cancer
In patients with metastatic urothelial cancer who received previous therapy, as well as in cisplatin-ineligible patients with this cancer, enfortumab vedotin-ejfv (Padcev) improved overall survival (OS), according to new data presented at the 2021 ASCO Genitourinary Cancers Symposium.
¹⁷⁷Lu-PSMA-617 Superior to Cabazitaxel in Metastatic Prostate Cancer
By
Patricia Stewart
TON - June 2021 Vol 14, No 3
Prostate Cancer
Cabazitaxel (Jevtana) is approved as third-line therapy for patients with metastatic castration-resistant prostate cancer (CRPC) after treatment with docetaxel and an androgen receptor inhibitor.
Many Postmenopausal Women with HR-Positive, HER2-Negative, Early-Stage Breast Cancer May Be Able to Skip Additional Chemotherapy
By
Patricia Stewart
TON - April 2021 Vol 14, No 2
Breast Cancer
Results of the SWOG S1007 RxPONDER clinical trial suggest that many postmenopausal women with early-stage hormone receptor (HR)-positive, human epidermal growth receptor 2 (HER2)-negative breast cancer, and 1 to 3 positive axillary lymph nodes may be able to avoid adjuvant chemotherapy.
Promising Results Seen with Ruxolitinib as Second-Line Treatment for Chronic GVHD
By
Patricia Stewart
TON - April 2021 Vol 14, No 2
Hematologic Malignancies
In a phase 3 clinical trial, ruxolitinib (Jakafi) led to superior overall response rates and durable responses compared with best available therapy (ie, control group) in patients with steroid-dependent or steroid-refractory chronic graft-versus-host disease (GVHD), with acceptable safety, according to results presented at ASH 2020.
Fixed-Duration Ibrutinib plus Venetoclax Regimen Promising as First-Line Treatment in CLL
By
Patricia Stewart
TON - April 2021 Vol 14, No 2
Hematologic Malignancies
The randomized phase 2 CAPTIVATE clinical trial showed that first-line therapy with ibrutinib (Imbruvica) and venetoclax (Venclexta) for a fixed duration (ie, 12 cycles) led to a 30-month progression-free survival (PFS) in more than 95% of patients with chronic lymphocytic leukemia (CLL) and undetectable minimal residual disease (MRD).
Xevinapant plus CRT Improves Survival in Patients with Locally Advanced HNSCC
By
Patricia Stewart
TON - December 2020, Vol 13, No 6
Emerging Therapies
Sotorasib Demonstrates Promising Antitumor Activity in Patients with Advanced NSCLC
By
Patricia Stewart
TON - December 2020, Vol 13, No 6
Emerging Therapies
CAR T-Cell Therapy May Not Be Needed for Select Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
By
Patricia Stewart
TON - December 2020, Vol 13, No 6
NCCN
Aggressive Approach to High-Risk Smoldering Myeloma Gains Consensus
By
Patricia Stewart
TON - December 2020, Vol 13, No 6
NCCN
Explosion of New Regimens for Multiple Myeloma: Selecting the Right Option for the Right Patient
By
Patricia Stewart
TON - December 2020, Vol 13, No 6
NCCN
At the National Comprehensive Cancer Network 2020 Virtual Congress: Hematologic Malignancies, multiple myeloma expert Shaji Kumar, MD, discussed the “bonanza of treatment regimens for multiple myeloma.” Although several new treatments and combination regimens have extended survival in patients with multiple myeloma, this cancer remains an incurable chronic disease, he said.
Nivolumab New Standard of Care in Gastroesophageal Cancers as First-Line or Adjuvant Therapy
By
Patricia Stewart
TON - December 2020, Vol 13, No 6
ESMO
,
ESMO 2020
Cabozantinib plus Nivolumab Offers New First-Line Treatment Option for Patients with Advanced Renal-Cell Carcinoma
By
Patricia Stewart
TON - December 2020, Vol 13, No 6
ESMO
,
ESMO 2020
Olaparib Significantly Improves Survival in Men with Metastatic Prostate Cancer and BRCA Mutations
By
Patricia Stewart
TON - December 2020, Vol 13, No 6
ESMO
,
ESMO 2020
“Practice-Changing” Results Seen with Adjuvant Abemaciclib plus Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer
By
Patricia Stewart
TON - December 2020, Vol 13, No 6
ESMO
,
ESMO 2020
Personalized Vaccine plus Atezolizumab Shows Promising Clinical Activity in Advanced Cancer
By
Patricia Stewart
TON - December 2020, Vol 13, No 6
Immunotherapy
Real-World Analysis Shows Survival Benefit with Adjuvant Immunotherapy in Melanoma
By
Patricia Stewart
TON - December 2020, Vol 13, No 6
Immunotherapy
COVID-19: Facing the Challenges Ahead
By
Patricia Stewart
TON - October 2020, Vol 13, No 5
AACR Highlights
“COVID-19 is more than just the common cold. It represents a perpetual challenge for which we have to be perpetually prepared,” stated Anthony S. Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases (NIAD), in his keynote lecture at the July 2020 AACR virtual meeting on COVID-19 and cancer.
COVID-19 Increases Overall Risk for Death in Patients with Cancer
By
Patricia Stewart
TON - October 2020, Vol 13, No 5
AACR Highlights
During the July 2020 AACR virtual meeting on COVID-19 and cancer, Solange Peters, MD, PhD, European Society for Medical Oncology President, and Head, Medical Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, delivered the keynote address, providing an update on the COVID-19 and Cancer Consortium cohort study.
Immune Checkpoint Inhibitors Do Not Increase Mortality in Patients with Cancer and COVID-19
By
Patricia Stewart
TON - October 2020, Vol 13, No 5
AACR Highlights
During the July 2020 AACR virtual meeting on COVID-19 and cancer, Solange Peters, MD, PhD, European Society for Medical Oncology President, and Head, Medical Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, delivered the keynote address, providing an update on the COVID-19 and Cancer Consortium cohort study.
Early Phase 2 Data Promising for 177lutetium PSMA-617 in Metastatic Prostate Cancer
By
Patricia Stewart
TON - August 2020, Vol 13, No 4
Prostate Cancer
Early results from the phase 2 TheraP clinical trial show that the targeted radiation therapy
177
Lutetium PSMA-617 (Lu-PSMA) significantly improved prostate-specific antigen (PSA) response compared with standard cabazitaxel in men with metastatic castration-resistant prostate cancer (CRPC) that progressed after docetaxel therapy.
Relugolix May Become New Standard of Care for Advanced Prostate Cancer
By
Patricia Stewart
TON - August 2020, Vol 13, No 4
Prostate Cancer
Oral relugolix given daily is superior to standard androgen-deprivation therapy (ADT) with leuprolide (Lupron) in men with advanced prostate cancer, according to the results of the phase 3 HERO study, which were reported at the ASCO 2020 virtual annual meeting and published online before the meeting (Shore ND, et al.
N Engl J Med
. 2020;382:2187-2196).
Durvalumab plus Chemotherapy Improves Overall Survival in Extensive-Stage Small-Cell Lung Cancer
By
Patricia Stewart
TON - August 2020, Vol 13, No 4
Lung Cancer
Updated results of the phase 3 CASPIAN clinical trial continue to show that durvalumab (Imfinzi) added to standard chemotherapy improves overall survival (OS) for patients with treatment-naïve extensive-stage small-cell lung cancer (ES-SCLC), according to a presentation at the ASCO 2020 virtual annual meeting.
Avelumab as Maintenance Prolongs Survival in Advanced Bladder Cancer
By
Patricia Stewart
TON - August 2020, Vol 13, No 4
Bladder Cancer
Interim analysis of the phase 3 JAVELIN Bladder 100 clinical trial showed that maintenance therapy with the PD-L1 inhibitor avelumab (Bavencio) plus best supportive care significantly prolonged overall survival (OS) versus best supportive care alone in patients with advanced urothelial carcinoma whose disease did not progress with first-line platinum-based chemotherapy.
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2023
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
2021
December 2021 - Vol 14 No 6
October 2021 - Vol 14 No 5
August 2021 - Vol 14 No 4
June 2021 - Vol 14 No 3
April 2021 - Vol 14 No 2
February 2021 - Vol 14 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Ovarian Cancer
HER2-Negative Breast Cancer
Triple-Negative Breast Cancer
Renal-Cell Carcinoma
Biosimilars
Gastrointestinal Cancer
Non–Small-Cell Lung Cancer
Categories
Conference Correspondent
ASCO 2021 - Breast Cancer
ASCO 2020 - Lung Cancer
ASH 2019 Wrap-Up
ASH 2019 MM
Web Exclusives
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Podcasts
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION